Key facts
- Precision Scientific (China)’s last known valuation is $126.3M (Jun 2023).
- It has raised $48.6M; the latest was Later Stage VC ($14.1M) in Dec 2025.
- Notable investors include SND Ventures Group, Baidu Ventures, Sinovation Ventures, CDBI Partners, Shenzhen GTJA Investment Group — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Precision Scientific (China)
- ·The full record, as it builds
Funding rounds
No funding rounds for Precision Scientific (China) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Precision Scientific (China)
Provider of AIBERT, an AI-native poly-omics exploration engine intended for novel medicine R&D and clinic-facing translation. The company provides mode-of-action mapping, signature derivation, trial design guidance, biostatistics, core laboratory operations, and companion assay co-development, enabling biopharma industry users with faster approval-track solutions.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2015
- Website
- precisionscientific.com/
- Ownership
- Privately Held (backing)
Precision Scientific (China) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Precision Scientific (China) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Precision Scientific (China) in its N-PORT filings yet. We sweep new filings monthly.